Literature DB >> 24246949

Label-free quantitative mass spectrometry reveals novel pathways involved in LL-37 expression.

Andreas Cederlund1, Frank Nylén, Erica Miraglia, Peter Bergman, Gudmundur H Gudmundsson, Birgitta Agerberth.   

Abstract

Antimicrobial peptides are important for a healthy host-microbe homeostasis. In infections characterized by low levels of the human cathelicidin, LL-37, induction of its expression increases clearance of pathogens. Our aim was to discover signaling pathways and compounds capable of affecting the expression of LL-37. We recently observed a synergistic induction of LL-37 expression by stimulating the colonic epithelial cell-line HT-29 with lactose and phenylbutyrate (PBA). Here, we studied regulatory circuits mediating this synergism in HT-29 cells stimulated with lactose (60 g/l) and PBA (2 mM) for 24 h by using mass spectrometry and pathway analyses. Selected pathways were evaluated for their involvement in LL-37 regulation in a CAMP gene-luciferase reporter system. Three pathways were examined in detail: thyroid hormone receptor and retinoid X receptor (TR/RXR) activation, eicosanoid signaling and steroid biosynthesis. Induced expression of LL-37 was observed upon stimulation with triiodothyronine (T3, 2.5 nM-1 µM for 3-30 h) and thyroxine (T4, 2.5-10 nM for 24 h). Furthermore, the synergism of lactose and PBA was reduced in cells coincubated with inhibitors of phospholipase A2, cyclooxygenase 2 or HMG-CoA reductase. Based on these results, we conclude that proteomics and pathway analyses are valuable tools for dissecting the regulatory networks involved in LL-37 expression.
© 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24246949      PMCID: PMC6741607          DOI: 10.1159/000355931

Source DB:  PubMed          Journal:  J Innate Immun        ISSN: 1662-811X            Impact factor:   7.349


  39 in total

1.  Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac.

Authors:  W S Chen; S J Wei; J M Liu; M Hsiao; J Kou-Lin; W K Yang
Journal:  Int J Cancer       Date:  2001-03-15       Impact factor: 7.396

2.  Irreversible inhibition of Ca(2+)-independent phospholipase A2 by methyl arachidonyl fluorophosphonate.

Authors:  Y C Lio; L J Reynolds; J Balsinde; E A Dennis
Journal:  Biochim Biophys Acta       Date:  1996-07-12

Review 3.  Prostaglandins and leukotrienes: advances in eicosanoid biology.

Authors:  C D Funk
Journal:  Science       Date:  2001-11-30       Impact factor: 47.728

Review 4.  Genetic variation in Toll-like receptors and disease susceptibility.

Authors:  Mihai G Netea; Cisca Wijmenga; Luke A J O'Neill
Journal:  Nat Immunol       Date:  2012-05-18       Impact factor: 25.606

5.  Novel roles of retinoid X receptor (RXR) and RXR ligand in dynamically modulating the activity of the thyroid hormone receptor/RXR heterodimer.

Authors:  Dangsheng Li; Tatsuya Yamada; Fang Wang; A Igor Vulin; Herbert H Samuels
Journal:  J Biol Chem       Date:  2003-12-10       Impact factor: 5.157

6.  Characterization of etoricoxib, a novel, selective COX-2 inhibitor.

Authors:  Aimee Dallob; Christopher J Hawkey; Howard Greenberg; Nicholas Wight; Paul De Schepper; Scott Waldman; Peggy Wong; Lisa DeTora; Barry Gertz; Nancy Agrawal; John Wagner; Keith Gottesdiener
Journal:  J Clin Pharmacol       Date:  2003-06       Impact factor: 3.126

7.  PU.1 and bacterial metabolites regulate the human gene CAMP encoding antimicrobial peptide LL-37 in colon epithelial cells.

Authors:  Stefan Termén; Maria Tollin; Eduardo Rodriguez; Sigrún H Sveinsdóttir; Bjarki Jóhannesson; Andreas Cederlund; Jan Sjövall; Birgitta Agerberth; Gudmundur H Gudmundsson
Journal:  Mol Immunol       Date:  2008-07-26       Impact factor: 4.407

8.  Gene expression profile analysis of 4-phenylbutyrate treatment of IB3-1 bronchial epithelial cell line demonstrates a major influence on heat-shock proteins.

Authors:  Jerry M Wright; Pamela L Zeitlin; Liudmila Cebotaru; Sandra E Guggino; William B Guggino
Journal:  Physiol Genomics       Date:  2004-01-15       Impact factor: 3.107

9.  Estrogen supports urothelial defense mechanisms.

Authors:  Petra Lüthje; Hanna Brauner; Nubia L Ramos; Amanda Ovregaard; Regine Gläser; Angelica Lindén Hirschberg; Pontus Aspenström; Annelie Brauner
Journal:  Sci Transl Med       Date:  2013-06-19       Impact factor: 17.956

10.  High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial.

Authors:  Adrian R Martineau; Peter M Timms; Graham H Bothamley; Yasmeen Hanifa; Kamrul Islam; Alleyna P Claxton; Geoffrey E Packe; John C Moore-Gillon; Mathina Darmalingam; Robert N Davidson; Heather J Milburn; Lucy V Baker; Richard D Barker; Nicholas J Woodward; Timothy R Venton; Korina E Barnes; Christopher J Mullett; Anna K Coussens; Clare M Rutterford; Charles A Mein; Geraint R Davies; Robert J Wilkinson; Vladyslav Nikolayevskyy; Francis A Drobniewski; Sandra M Eldridge; Christopher J Griffiths
Journal:  Lancet       Date:  2011-01-05       Impact factor: 79.321

View more
  3 in total

1.  Evidence that the Human Innate Immune Peptide LL-37 may be a Binding Partner of Amyloid-β and Inhibitor of Fibril Assembly.

Authors:  Ersilia De Lorenzi; Marcella Chiari; Raffaella Colombo; Marina Cretich; Laura Sola; Renzo Vanna; Paola Gagni; Federica Bisceglia; Carlo Morasso; Jennifer S Lin; Moonhee Lee; Patrick L McGeer; Annelise E Barron
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

2.  Human antimicrobial peptides and proteins.

Authors:  Guangshun Wang
Journal:  Pharmaceuticals (Basel)       Date:  2014-05-13

Review 3.  Role of Microbes in the Development of Alzheimer's Disease: State of the Art - An International Symposium Presented at the 2017 IAGG Congress in San Francisco.

Authors:  Tamàs Fülöp; Ruth F Itzhaki; Brian J Balin; Judith Miklossy; Annelise E Barron
Journal:  Front Genet       Date:  2018-09-10       Impact factor: 4.599

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.